{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-016821","form_type":"8-K","ticker":"PLSE","cik":"0001625101","company_name":"PULSE BIOSCIENCES, INC.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.302454+00:00","generated_at":"2026-06-01T23:12:38.145319+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pulse Biosciences appoints Burke T. Barrett as CEO; Kevin Danahy becomes Chief Commercial Officer","bullets":["Burke T. Barrett named President and CEO effective May 12, 2024; succeeds Kevin Danahy who becomes Chief Commercial Officer.","Barrett previously CEO of CardioFocus, led global commercial launch of atrial fibrillation laser-balloon ablation device.","Barrett receives options to purchase 1.4M shares at $7.45, half time-vested over 4 years, half upon $1B-$4B market cap milestones.","Danahy and CTO Darrin Uecker amend employment agreements to reduce severance salary continuation from 12 to 3 months (12 months post-change of control)."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-016821","json":"https://secwatch.observer/filing/0001437749-24-016821.json","markdown":"https://secwatch.observer/filing/0001437749-24-016821.md","text":"https://secwatch.observer/filing/0001437749-24-016821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924016821/0001437749-24-016821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924016821/plse20240513_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:12:38.145319+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"05c41ef50c","claim":"Burke T. Barrett was appointed as President and Chief Executive Officer at PULSE BIOSCIENCES, INC..","evidence_excerpt":"The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Burke T. Barrett as President and Chief Executive Officer of the Company and as a director, in each case effective as of May 12, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924016821/0001437749-24-016821-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}]},{"claim_id":"952c89c890","claim":"Burke T. Barrett was appointed as Director at PULSE BIOSCIENCES, INC..","evidence_excerpt":"The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Burke T. Barrett as President and Chief Executive Officer of the Company and as a director, in each case effective as of May 12, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924016821/0001437749-24-016821-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}]},{"claim_id":"fffe420980","claim":"Kevin P. Danahy was appointed as Chief Commercial Officer at PULSE BIOSCIENCES, INC..","evidence_excerpt":"Mr. Barrett succeeds Kevin P. Danahy, who was appointed as the Company’s Chief Commercial Officer, as of the Start Date","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1625101/000143774924016821/0001437749-24-016821-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Commercial Officer"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}